ストックスクリーナーアプリを入手
3.83
4.25%
-0.17
アフターアワーズ：
3.84
0.010
+0.26%
前日終値:
$4.00
開ける：
$4
24時間の取引高:
1.74M
Relative Volume:
0.81
時価総額：
$397.87M
収益：
-
当期純損益:
$-166.01M
株価収益率:
-1.8433
EPS:
-2.0778
ネットキャッシュフロー:
$-131.32M
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
+4.64%
6か月 パフォーマンス:
+4.36%
1年 パフォーマンス:
-1.29%
1日の値動き範囲:
$3.805
$4.06
1週間の範囲:
$3.74
$4.17
52週間の値動き範囲:
$2.715
$6.42
Larimar Therapeutics Inc Stock (LRMR) Company Profile
名前
Larimar Therapeutics Inc
セクター
電話
844-511-9056
住所
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR vs VRTX, REGN, ARGX, RVMD, ALNY
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
3.83 | 415.53M | 0 | -166.01M | -131.32M | -2.0778 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-29 | 開始されました | Truist | Buy |
| 2024-10-16 | 開始されました | Oppenheimer | Outperform |
| 2024-10-03 | 開始されました | Wedbush | Outperform |
| 2024-10-02 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-04 | 開始されました | Robert W. Baird | Outperform |
| 2024-04-03 | 開始されました | Leerink Partners | Outperform |
| 2023-11-17 | アップグレード | Citigroup | Neutral → Buy |
| 2022-10-19 | 開始されました | Guggenheim | Buy |
| 2022-02-15 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-02-10 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-02-01 | 開始されました | William Blair | Outperform |
すべてを表示
Larimar Therapeutics Inc (LRMR) 最新ニュース
A Deeper Dive Into Design Therapeutics (NASDAQ:DSGN) - Seeking Alpha
Larimar Therapeutics Inc (LRMR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Larimar Therapeutics Inc (LRMR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
LRMR|Larimar Therapeutics Inc|Price:3.820|Chg%:-0.180 - TradingKey
Enterprise value to EBITDA forward of Larimar Therapeutics, Inc. – NASDAQ:LRMR - TradingView
TradingKey - TradingKey
Larimar Therapeutics Market Sentiment - Benzinga España
Larimar Therapeutics, Inc. Revenue Breakdown – NASDAQ:LRMR - TradingView
What Just Happened with Larimar Therapeutics (LRMR) and Why Does it Matter - Kavout | AI
LRMR|Larimar Therapeutics Inc|Price:4.000|Chg%:-0.010 - TradingKey
Larimar Therapeutics Inc (LRMR) Institutional Confidence - TradingKey
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc.LRMR - PR Newswire
LifeSci Capital Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Price to earnings forward of Larimar Therapeutics, Inc. – SWB:ZA71 - TradingView
Larimar Therapeutics Files First Module of BLA for Nomlabofusp in Friedreich's Ataxia TreatmentNew Analyst Coverage - dars.gov.et
Larimar Therapeutics Initiates BLA Submission for Nomlabofusp in Friedreich’s AtaxiaProfit Guidance Range - dars.gov.et
Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy - Yahoo Finance
Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? - Stocktwits
Price to earnings forward of Larimar Therapeutics, Inc. – LS:A2P5PP - TradingView
Larimar Prices $100M Stock Sale After Record Rally Fueled By FDA Breakthrough Tag For Protein Replacement Therapy - Stocktwits
Price to sales forward of Larimar Therapeutics, Inc. – NASDAQ:LRMR - TradingView
Thomas Hamilton Bought 6.1% More Shares In Larimar Therapeutics - Moomoo
Larimar Therapeutics stock jumps on insider purchase By Investing.com - Investing.com South Africa
Larimar Therapeutics stock jumps on insider purchase - Investing.com
Larimar Therapeutics director buys $166,890 in company stock - Investing.com UK
Enterprise value to revenue forward of Larimar Therapeutics, Inc. – SWB:ZA71 - TradingView
LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000 - TradingView
Larimar Therapeutics director buys $166,890 in company stock By Investing.com - Investing.com South Africa
Form 4 Larimar Therapeutics Inc For: 8 July By Investing.com - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
Larimar Therapeutics (LRMR) director purchases 50,000 common shares - Stock Titan
Law firm probes Larimar Therapeutics for possib... - Pluang
Larimar Starts FDA Filing for FA Drug With Mid-2027 Goal - MyChesCo
LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns - Stocktwits
Here’s What Citi Thinks About Larimar Therapeutics (LRMR) - Insider Monkey
H.C. Wainwright initiates Larimar stock coverage with buy rating - Investing.com UK
LRMR Assumed by HC Wainwright & Co. -- Rating Set to Buy - GuruFocus
H.C. Wainwright initiates Larimar stock coverage with buy rating By Investing.com - Investing.com South Africa
Larimar Therapeutics Coverage Assumed by HC Wainwright & Co. at Buy - Moomoo
Price to book forward of Larimar Therapeutics, Inc. – NASDAQ:LRMR - TradingView
H.C. Wainwright Initiates Larimar Therapeutics(LRMR.US) With Buy Rating, Announces Target Price $10 - Moomoo
Larimar Therapeutics Up Nearly 32%, on Pace for Largest Percent Increase Since February 2024 -- Data Talk - Moomoo
Citi Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Larimar Therapeutics, Inc. (LRMR) Discusses Regulatory Progress and Long-Term Data for Nomlabofusp in Friedreich's AtaxiaSlideshow (NASDAQ:LRMR) 2026-07-01 - Seeking Alpha
Enterprise value to EBIT forward of Larimar Therapeutics, Inc. – LS:A2P5PP - TradingView
Larimar Therapeutics | 8-K: Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Moomoo
Here's Why We're Watching Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation - Moomoo
Wedbush Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $12 - Moomoo
LRMR Maintains by Baird -- Price Target Lowered to $5.00 - GuruFocus
Larimar Therapeutics Inc (LRMR) 財務データ
収益
当期純利益
現金流量
EPS
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):